Haiko J. Bloemendal
Nijmegen, GE, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
Comprehensive Cancer Networks in the Netherlands: how do they affect quality and costs of care for colon or pancreatic cancer? A retrospective cohort study.
Journal: BMJ open
Published: January 29, 2026
Stakeholders' experiences with a clinician-led access programme linking evidence generation and reimbursement for precision cancer treatments: the drug access protocol in the Netherlands.
Journal: Acta oncologica (Stockholm, Sweden)
Published: November 05, 2025
Mapping drug-drug interactions in pharmacokinetic boosting of olaparib.
Journal: Cancer chemotherapy and pharmacology
Published: September 01, 2025
Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis.
Journal: European urology focus
Published: June 25, 2025
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.
Journal: British journal of cancer
Published: December 03, 2024
Cancer incidence and diagnostic characteristics in people with intellectual disabilities in the Netherlands: a national registry-based cohort study.
Journal: BMJ oncology
Published: November 27, 2024
Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B).
Journal: Contemporary clinical trials communications
Published: November 05, 2024
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 13, 2024
The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer.
Journal: Scientific reports
Published: June 17, 2024
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
Journal: Theranostics
Published: February 01, 2024
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients.
Journal: Cancer chemotherapy and pharmacology
Published: January 28, 2024
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Journal: The Lancet regional health. Europe
Published: January 02, 2024
Last Updated: 09/26/2026